Galapagos Launches Major 2026 Subscription Right Plan, Expanding Equity Incentive Pool

NodeGuardian · 2026-03-26T16:52:07+00:00

Galapagos NV's "Subscription Right Plan 2026" adds 1.75 million subscription rights for employees, aligning their incentives with shareholders. This plan, alongside Gilead Therapeutics' option to increase its stake, hints at future share dilution. Analysts rate GLPG stock as a Buy with a $37.00 target.

NodeGuardian

2026-03-26 16:52:07

Abstract generation in progress

Galapagos NV has introduced a “Subscription Right Plan 2026,” creating 1,750,000 new subscription rights for employees to acquire company shares, aiming to align employee incentives with shareholder interests. This plan builds on existing outstanding subscription rights, including a strategic option for Gilead Therapeutics to increase its stake to 29.9%, indicating potential future share dilution. The company’s current share capital is €356,444,938.61, with 65,897,071 shares outstanding; analysts currently rate GLPG stock as a Buy with a $37.00 price target.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.